SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Public ClinicalTrials.gov record NCT04150042. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
Study identification
- NCT ID
- NCT04150042
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- General Oncology, Inc.
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
- Adenocarcinoma of the Breast
- BRCA1 Mutation
- BRCA2 Mutation
- Breast Cancer Metastatic
- Breast Cancer Stage IV
- HER2 Negative Breast Carcinoma
- HER2-negative Breast Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- PALB2 Gene Mutation
- Pancreas Cancer
- Pancreas Cancer, Metastatic
- Pancreas Cancer, Recurrent
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Cancer
- Pancreatic Cancer Stage IV
- Pancreatic Ductal Adenocarcinoma
- Stage 4 Pancreatic Cancer
- Stage IV Pancreatic Cancer
Interventions
- Autologous Hematopoietic Stem Cells Device
- BCNU Drug
- Melphalan Drug
- Vitamin B12B Drug
- Vitamin C Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2021
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Jan 28, 2026
2021 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04150042, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04150042 live on ClinicalTrials.gov.